[go: up one dir, main page]

AU2001231091A1 - Identification of genetic components of drug response - Google Patents

Identification of genetic components of drug response

Info

Publication number
AU2001231091A1
AU2001231091A1 AU2001231091A AU3109101A AU2001231091A1 AU 2001231091 A1 AU2001231091 A1 AU 2001231091A1 AU 2001231091 A AU2001231091 A AU 2001231091A AU 3109101 A AU3109101 A AU 3109101A AU 2001231091 A1 AU2001231091 A1 AU 2001231091A1
Authority
AU
Australia
Prior art keywords
identification
drug response
genetic components
genetic
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231091A
Other languages
English (en)
Inventor
Vincent P. Stanton Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Variagenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variagenics Inc filed Critical Variagenics Inc
Publication of AU2001231091A1 publication Critical patent/AU2001231091A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Social Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001231091A 2000-01-21 2001-01-22 Identification of genetic components of drug response Abandoned AU2001231091A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17752200P 2000-01-21 2000-01-21
US60177522 2000-01-21
PCT/US2001/002223 WO2001053460A1 (fr) 2000-01-21 2001-01-22 Identification de composantes genetiques dans une reaction au medicament

Publications (1)

Publication Number Publication Date
AU2001231091A1 true AU2001231091A1 (en) 2001-07-31

Family

ID=22648916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231091A Abandoned AU2001231091A1 (en) 2000-01-21 2001-01-22 Identification of genetic components of drug response

Country Status (4)

Country Link
US (3) US20020012921A1 (fr)
EP (1) EP1248832A4 (fr)
AU (1) AU2001231091A1 (fr)
WO (1) WO2001053460A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US20020187483A1 (en) * 2001-04-20 2002-12-12 Cerner Corporation Computer system for providing information about the risk of an atypical clinical event based upon genetic information
US20030022206A1 (en) * 2001-05-16 2003-01-30 Kay Robert A. Method of characterizing a homeopathic preparation
US20050074868A1 (en) * 2001-07-06 2005-04-07 Nicholas Schork Method of genomic analysis
GB0116565D0 (en) * 2001-07-06 2001-08-29 King S College Method of analysis
US20080026367A9 (en) * 2001-08-17 2008-01-31 Perlegen Sciences, Inc. Methods for genomic analysis
US7461006B2 (en) * 2001-08-29 2008-12-02 Victor Gogolak Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data
US7983848B2 (en) * 2001-10-16 2011-07-19 Cerner Innovation, Inc. Computerized method and system for inferring genetic findings for a patient
US20030108938A1 (en) * 2001-11-06 2003-06-12 David Pickar Pharmacogenomics-based clinical trial design recommendation and management system and method
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
WO2003050533A1 (fr) * 2001-12-10 2003-06-19 Ardais Corporation Systeme et procedes permettant d'obtenir des prelevements de patients en correlation avec des donnees
US6904434B1 (en) 2001-12-18 2005-06-07 Siebel Systems, Inc. Method and system for providing real-time clinical trial enrollment data
EP1490023A4 (fr) * 2002-02-28 2006-07-12 Iconix Pharm Inc Signatures de medicaments
US7427480B2 (en) * 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040122714A1 (en) * 2002-12-23 2004-06-24 Siemens Aktiengesellschaft Method for conducting a clinical study
JP5348840B2 (ja) * 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20040202571A1 (en) * 2003-04-10 2004-10-14 Epler Gary R. Directed medication system and method
US20070026406A1 (en) * 2003-08-13 2007-02-01 Iconix Pharmaceuticals, Inc. Apparatus and method for classifying multi-dimensional biological data
US7335474B2 (en) * 2003-09-12 2008-02-26 Perlegen Sciences, Inc. Methods and systems for identifying predisposition to the placebo effect
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
WO2006001896A2 (fr) * 2004-04-26 2006-01-05 Iconix Pharmaceuticals, Inc. Puce a adn universelle pour analyse chimiogenomique a haut rendement
WO2005124650A2 (fr) * 2004-06-10 2005-12-29 Iconix Pharmaceuticals, Inc. Ensemble de reactifs suffisants et necessaires utilises a des fins d'analyse chimiogenomique
US20060069074A1 (en) * 2004-07-07 2006-03-30 Lemanske Robert F Jr Genetic predictor of efficacy of anti-asthmatic agents for improving pulmonary function
WO2006017156A2 (fr) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Procedes pour identifier un candidat pour le traitement de l'obesite
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
FR2887663A1 (fr) * 2005-06-24 2006-12-29 Ippm Holding Sa Procede et systeme d'information pour generer des donnees d'optimisation d'un traitement medical, et equipement mis en oeuvre dans ce systeme
CA2911569C (fr) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimisation et personnalisation de selection et de dosage de medicaments
CA2631675A1 (fr) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification de variants polymorphiques genetiques associes aux troubles somatosensoriels et procedes d'utilisation de ces derniers
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
US20070198653A1 (en) * 2005-12-30 2007-08-23 Kurt Jarnagin Systems and methods for remote computer-based analysis of user-provided chemogenomic data
US20070179809A1 (en) * 2005-12-30 2007-08-02 Brown Melissa M System and method for performing a cost-utility analysis of pharmaceutical interventions
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US8579811B2 (en) * 2006-09-19 2013-11-12 3M Innovative Properties Company Medical diagnosis derived from patient drug history data
US20100021885A1 (en) * 2006-09-18 2010-01-28 Mark Fielden Reagent sets and gene signatures for non-genotoxic hepatocarcinogenicity
EP3216874A1 (fr) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Procédés pour la stratification et l'annotation des options de traitement médicamenteux contre le cancer
EP2601609B1 (fr) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions et méthodes de recherche de mutations causales dans des troubles génétiques
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
EP2766483B1 (fr) 2011-10-10 2022-03-23 The Hospital For Sick Children Méthodes et compositions de dépistage et de traitement de troubles du développement
EP2773779B1 (fr) 2011-11-04 2020-10-14 Population Bio, Inc. Méthodes et compositions pour le diagnostic, le pronostic et le traitement d'états neurologiques
WO2013120018A1 (fr) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Méthodes et compositions permettant de rechercher et de traiter des troubles du développement
EP2668945A1 (fr) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Formulations de médicament basées sur un génotype ou un phénotype
US10457978B2 (en) * 2012-08-17 2019-10-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclopentane-peptide nucleic acids for qualitative and quantitative detection of nucleic acids
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
EP2900835B1 (fr) 2012-09-27 2025-04-30 Population Bio, Inc. Procédé de dépistage et de traitement de troubles du développement
WO2014121133A2 (fr) * 2013-02-03 2014-08-07 Genelex Corporation Systèmes et procédés permettant de quantifier et de présenter le risque médical découlant de facteurs inconnus
US20140274764A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
CA2921981A1 (fr) * 2013-09-03 2015-03-12 Coyne Ip Holdings, Llc Procedes pour des etudes d'association de genes sur la base d'une reponse a un stimulus genetiquement diversifie
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
WO2019126372A1 (fr) * 2017-12-20 2019-06-27 Heartflow, Inc. Systèmes et procédés pour effectuer une évaluation de traitements simulée par ordinateur sur une population cible
US11380424B2 (en) 2018-06-15 2022-07-05 Xact Laboratories Llc System and method for genetic based efficacy testing
US11227685B2 (en) 2018-06-15 2022-01-18 Xact Laboratories, LLC System and method for laboratory-based authorization of genetic testing
US12217874B2 (en) 2018-06-15 2025-02-04 Xact Laboratories, LLC System and method for suggesting insurance eligible genetic efficacy tests
US11527331B2 (en) 2018-06-15 2022-12-13 Xact Laboratories, LLC System and method for determining the effectiveness of medications using genetics
US12354724B2 (en) 2018-06-15 2025-07-08 Xact Laboratories, LLC Automated prior authorization for genetic efficacy testing with prescription dispensation
US11398312B2 (en) 2018-06-15 2022-07-26 Xact Laboratories, LLC Preventing the fill of ineffective or under-effective medications through integration of genetic efficacy testing results with legacy electronic patient records
CA3108807A1 (fr) 2018-08-08 2020-02-13 Pml Screening, Llc Procedes pour evaluer le risque de developper une leucoencephalopathie multifocale progressive provoquee par le virus de john cunningham par des procedes de test genetique pour ev aluer le risque de developper une leucoencephalopathie multifocale progressive provoquee par le virus de john cunningham par test genetique
WO2020041204A1 (fr) * 2018-08-18 2020-02-27 Sf17 Therapeutics, Inc. Analyse d'intelligence artificielle de transcriptome d'arn pour la découverte de médicament
CN117079762B (zh) * 2023-09-25 2024-01-23 腾讯科技（深圳）有限公司 药物效果预测模型训练方法、药物效果预测方法及其装置
WO2025240664A1 (fr) * 2024-05-15 2025-11-20 Foresite Labs, Llc Développement de médicament et détermination d'activité de médicament pour une maladie hépatique chronique, une nash, une adiposité et un diabète

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2548602A (en) * 1948-04-09 1951-04-10 Greenburg Leonard Inflatable dilator
US3517702A (en) * 1966-07-08 1970-06-30 Amp Inc Flexible material to form a tubular member
US3495306A (en) * 1967-11-01 1970-02-17 Plummer Walter A Variable width seam of interlocking components
US3654049A (en) * 1970-04-30 1972-04-04 Steven Ausnit Self-retaining extruded plastic wrap member
US4646722A (en) * 1984-12-10 1987-03-03 Opielab, Inc. Protective endoscope sheath and method of installing same
FR2595617B1 (fr) * 1986-03-17 1988-09-09 Gefrem Dispositif de fermeture a pression pour reunir les bords de nappes en matiere plastique
DE3734993A1 (de) * 1987-09-03 1989-04-27 Asf Verwaltungsgesellschaft Mb Verschlussband aus kunststoff
US4815470A (en) * 1987-11-13 1989-03-28 Advanced Diagnostic Medical Systems, Inc. Inflatable sheath for ultrasound probe
US4886049A (en) * 1988-05-17 1989-12-12 Darras Robert L Medical instrument cover
US5025778A (en) * 1990-03-26 1991-06-25 Opielab, Inc. Endoscope with potential channels and method of using the same
US5645988A (en) * 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
CH691245A5 (de) * 1996-01-12 2001-05-31 Epcos Ag Gasgefüllte Entladungsstrecke.
US5955355A (en) * 1997-03-27 1999-09-21 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
JP2003516111A (ja) * 1999-02-22 2003-05-13 バリアジェニックス インコーポレーテッド 疾病の治療法の決定において有用性を有する遺伝子配列変異

Also Published As

Publication number Publication date
EP1248832A1 (fr) 2002-10-16
EP1248832A4 (fr) 2004-07-07
US20020012921A1 (en) 2002-01-31
WO2001053460A1 (fr) 2001-07-26
US20070072232A1 (en) 2007-03-29
US20040082000A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AU2001231091A1 (en) Identification of genetic components of drug response
EP1322071A3 (fr) Identification d'un terminal
AU2002326691A1 (en) Identification of sortase gene
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2001288360A1 (en) Genomics-assisted rapid identification of targets
AU2001266225A1 (en) Decondensation of dna
AU2001288061A1 (en) Drug resistance-associated gene and use thereof
AU2001232948A1 (en) Controlled release of drugs
AU2002365188A1 (en) Nucleic acid delivery and expression
AU2002219900A1 (en) Minimal identification of features
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2000275763A1 (en) Expression of functional eukaryotic proteins
AU2001232244A1 (en) Drug comprising combination
AU2001264247A1 (en) GASC1 gene
AUPQ596600A0 (en) Point of sale system
AU2001292301A1 (en) Novel drugs for liver diseases
AU2001247444A1 (en) Erbeta-mediated gene expression
AU7567101A (en) Gene expression system
AU2001285743A1 (en) Adipose-related gene
AU2001284265A1 (en) Genetic study
AU2002240921A1 (en) Medane genes and proteins
AU3865400A (en) Animal model of allergies
AU9519601A (en) Identification of genetic markers
AU2002361450A1 (en) Novel pharmaceutical
AU2002240837A1 (en) Identification of lead structures